peppersite
Peptideintranasal

Semax

Semax is a lab-made peptide of seven amino acids, built from a piece of the stress hormone ACTH with a short tail added to slow its breakdown. It is studied mainly as a nasal spray in rats and in Russian clinical work on stroke recovery, stress and cognition.

Researched for
Neuroinflammation

At a glance

Type
Peptide
Given by
intranasal
Evidence
AnimalAnimal, across 6 audits
Reported amount
0.6 mg per Peptide Dosing Protocols. All 4 sources

How much to draw

Full calculator →
Your draw
–units
Fill in the three numbers to see the draw.
Amount per dose

Opened on 0.6 mg, the figure Peptide Dosing Protocols reports for Semax. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for Semax or for anything else, and nothing below has been checked against the study it came from.

Standard: 0.6 to 1.5 mg/day · Low: sub-milligram per administration · High: up to ~1 mg/kg
Frequency
Daily administration, often divided into morning and afternoon doses10-14 days for standard short course, 4-6 weeks for extended cognitive course · 4-6 weeks on, 2-4 weeks off
Route
Intranasal solution, Subcutaneous injection
Reported by
Peptide Dosing Protocols
What it saysStandard dosing for Semax is about 0.6 to 1.5 mg per day, typically split into two administrations.
300-600 mcg intranasally daily (or 1-3 drops/nostril of 0.1% solution)
Frequency
once or twice daily10-14 day cycles · Repeat cycles per provider direction
Route
intranasal
Reported by
Commonly published practitioner dosing range - provider confirmation required.
200-600 mcg per dose (0.1% solution) for nootropic use; 3-6 mg per dose (1% solution) for stroke
Frequency
2-3 times dailyRepeatable
Route
intranasal
Reported by
Peptide Protocol Wiki
Referenced at 300-600 mcg (0.3-0.6 mg) daily in brain health protocols. Morning administration cited to carry cognitive benefit through the day. Rotation with other nootropic peptides between cycles referenced to maintain response.
Frequency
Daily · Morning4 weeks on with rotation between cycles
Route
nasal
Reported by
Peptide Therapy Reference Text
What it saysAug 2026), secondary reference; provider confirmation required.
Reconstitution, as reported
  • Requires reconstitution with bacteriostatic water before subcutaneous research use
  • Compounded intranasal solution/spray · Compounded intranasal solution - no reconstitution required
What our audits found
Animalstrongest evidence cited across 6 audits · animal

"Approved in Russia Since the 1990s." That's a Fact About Russia, Not About Semax.

I sell Semax, and when I followed the claims about it back to their sources, most of them stopped within two clicks. Here's how to tell which ones stop where.

12 CLAIMS GRADED

"It's an Approved Drug in Russia." That's the Weakest Argument for Semax, Not the Strongest.

Semax has a real evidence base, which is exactly what makes it easy to overstate: almost none of it was collected in healthy people at a desk, and almost nobody outside its home research tradition has checked it.

12 CLAIMS GRADED

Semax Isn't Under-Researched. It's Under-Translated.

Decades of work exists on this peptide. Almost nothing an English reader can actually open says a word about human cognition, and I sell the stuff.

11 CLAIMS GRADED

Semax Has Been Used Clinically for Decades. That's a Claim About Russia, Not About Cognition.

The most convincing sentence in the Semax conversation is a fact about a healthcare system, and buyers keep mistaking it for evidence about a molecule.

12 CLAIMS GRADED

Everyone Opens With "Semax Is Approved in Russia." Approval and Replication Are Two Different Columns.

A three-column test for reading any compound whose evidence sits behind a language border, and what the English-language literature on Semax actually contains.

10 CLAIMS GRADED

Semax Is Approved in Russia. That's a Fact About a Regulator, Not a Result.

I went looking for the human trial I could hand you and came back with mice, a negative result, and one honest reason the Western data is thin.

11 CLAIMS GRADED

How it is thought to work

Semax appears to nudge the brain's repair and plasticity programs, and its effects show up most clearly when the brain is under strain, such as stress, injury, fatigue or heavy mental load, rather than at rest. Researchers link this to higher BDNF protein and TrkB receptor signaling in rat hippocampus, changes in dopamine and serotonin systems in rodents, possible partial action at MC4 and MC5 melanocortin receptors, and blocking of enkephalin-breaking enzymes. The receptor picture is not settled, and there is no published Western Phase 2 or Phase 3 randomized trial, nor any head-to-head trial against modafinil, racetams, caffeine with L-theanine, or placebo in healthy adults.

In technical termsBDNF-related and neuro-signaling pathways.

What we don't know

Healthy adults: our audits could not find a controlled trial of Semax on cognition in healthy people that can be read in full in English. No Western Phase 2 or Phase 3 randomized controlled trial has been published.

The Russian record: the clinical work behind its Russian registration is largely untranslated, and we could not read or check it. The audits say this makes it unverified, not false.

Independent replication: the audits found almost no sign that groups outside the original research tradition have repeated the findings.

Safety and mechanism: the Alzheimer's Drug Discovery Foundation reported very little human evidence on side effects. The full receptor profile is described as not settled.

Reported side effects

Seen in studies: the Alzheimer's Drug Discovery Foundation reported very little human evidence on side effects despite many preclinical trials, and described nasal cavity discoloration in roughly 10 percent of people using the nasal route. Higher blood sugar has been reported specifically in people with diabetes.

Reported by users: a feeling of being too activated, especially alongside caffeine or stimulants or late in the day, along with nasal irritation, sneezing and dryness, and trouble falling asleep after late-day use.

Not ruled out: the FDA's 503A Category 2 listing flagged Semax for immunogenicity risk on certain routes, because of possible clumping of the peptide and peptide-related impurities. That concern is about how a batch is made, handled and stored rather than the molecule itself, and the 2026 removal from that category was a procedural withdrawal, not a safety clearance.

Who should avoid it

People with diabetes: it may raise blood sugar, according to the ADDF and Russian-language safety summaries.

People who are pregnant or breastfeeding: there is not enough human research to judge safety for a fetus or infant, and the ADDF lists both as contraindications.

People with high baseline anxiety: a 1996 study described an anxiety-producing component in some research subjects, so it may amplify anxiety in people who are already anxious.

People taking psychiatric or stimulant medications: Semax affects dopamine and serotonin systems in animal models, so combining it with SSRIs, SNRIs, MAOIs, stimulants or sleep medicines is flagged as needing clinician oversight.

Anyone using research-grade product with no quality data: the FDA's compounding-risk language names clumping and peptide-related impurities for Semax, and product quality risk can exceed the risk of the molecule.

Regulatory status

FDA approval: Semax is not an FDA-approved drug in the United States.

Compounding: the FDA listed Semax in 503A Category 2 and flagged an immunogenicity risk on certain routes, linked to possible clumping of the peptide and peptide-related impurities. The reference entry says it was removed from that category in 2026 and describes the removal as a procedural withdrawal, not a safety clearance.

Outside the US: our audits describe Semax as registered as a medicine in Russia, with decades of clinical use there for disease indications such as stroke. They stress that a registration shows a regulator accepted a dossier under its own standards, not that the FDA or the European Medicines Agency reviewed anything. The reference entry says Semax is not authorized as a medicine by the UK Medicines and Healthcare products Regulatory Agency.

Checked: November 2026.

Common questions

What is Semax?

Semax is a lab-made peptide of seven amino acids, built from a fragment of the stress hormone ACTH with a stabilizing tail attached. It is usually studied as a nasal spray in brain-protection and cognition research.

What does Semax do?

Reports describe it as nudging the brain's plasticity programs and stress-response biology. The most cited finding is higher BDNF protein and TrkB receptor signaling in rat hippocampus after a single nasal dose.

Is Semax FDA-approved?

No. Semax is not an FDA-approved drug in the United States. No Western Phase 2 or Phase 3 randomized controlled trial has been published for it.

What amounts do sources report for Semax?

Reported amounts and schedules for Semax differ by source, and peppersite does not recommend one. Each reported figure is listed in the dosing rows on this page, next to the source that reports it.

Selank and Semax: what is the difference?

Semax is associated in the literature with cognitive activation and brain protection. Selank is associated with calming and stress-modulating effects, and sources describe it as the closer fit when the goal is a calmer feel.

Is Semax nasal spray legal in the UK?

Semax is not authorized as a medicine by the UK Medicines and Healthcare products Regulatory Agency. It is also not an FDA-approved drug in the United States.

Can Semax and Selank be used together?

Pairing the two is a planning idea within the research community, not a clinically validated combination. No trial supports the pairing.

How fast does Semax work?

Intranasal Semax is described as fast in onset, with same-day reports of changes in attention or getting started on tasks. The reported effects are strongest in stress, stroke-recovery and heavy-workload settings rather than in well-rested healthy volunteers.

Sources

The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.

Studied for the same things